Low-molecular-weight heparin and survival in lung cancer

Noble, Simon Ian Robert ORCID: https://orcid.org/0000-0001-5425-2383 2012. Low-molecular-weight heparin and survival in lung cancer. Thrombosis Research 129 (S1) , S114-S118. 10.1016/S0049-3848(12)70029-4

Full text not available from this repository.

Abstract

Therapeutic developments have seen significant improvement in mortality over the past thirty years for breast, colorectal and prostate cancer. Lung cancer is the commonest cancer in the world, but has seen little improvement in survival figures. The role of low-molecular-weight heparin (LMWH) in improving cancer survival has attracted increasing attention over the past decade. There are several clinical trials underway focussing specifically on LMWH and lung cancer survival. This article will review the evidence, to date, that supports the hypothesis that LMWH may improve lung cancer survival through several potential mechanisms; by preventing VTE-related mortality or by the exhibiting antimetastatic effects.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords:	LMWH, lung cancer, thrombosis, survival
Publisher:	Elsevier
ISSN:	0049-3848
Last Modified:	21 Oct 2022 10:46
URI:	https://orca.cardiff.ac.uk/id/eprint/41308

Citation Data

Cited 19 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item